Literature DB >> 15163359

Transgenic mouse models of Alzheimer's disease: how useful have they been for therapeutic development?

Karen Duff1, Faraha Suleman.   

Abstract

Transgenic mice have been created in an attempt to generate models of human Alzheimer's disease, but success has been partial and unpredictable. The overall aim of this paper is to illustrate how genomics can be used in translational research, turning genetic information in the form of pathogenic mutations into clinically useful drugs against a major human disease. This paper will illustrate how genetic information allows researchers to dissect the aetiology of a disease and then replicate the disease in vivo through the process of transgenesis. The limitations of recreating a condition like Alzheimer's disease in a transgenic mouse, how far the mice have advanced understanding of the disease and how useful they have been for the development of therapeutics will then be discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163359     DOI: 10.1093/bfgp/3.1.47

Source DB:  PubMed          Journal:  Brief Funct Genomic Proteomic        ISSN: 1473-9550


  34 in total

Review 1.  Obesity, leptin, and Alzheimer's disease.

Authors:  Edward B Lee
Journal:  Ann N Y Acad Sci       Date:  2011-12       Impact factor: 5.691

2.  Prediction of S-glutathionylated proteins progression in Alzheimer's transgenic mouse model using principle component analysis.

Authors:  Cheng Zhang; Ching-Chang Kuo; Alan W L Chiu; June Feng
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 3.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

Review 4.  Dendritic vulnerability in neurodegenerative disease: insights from analyses of cortical pyramidal neurons in transgenic mouse models.

Authors:  Jennifer I Luebke; Christina M Weaver; Anne B Rocher; Alfredo Rodriguez; Johanna L Crimins; Dara L Dickstein; Susan L Wearne; Patrick R Hof
Journal:  Brain Struct Funct       Date:  2010-02-24       Impact factor: 3.270

5.  Neurotoxic effects induced by the Drosophila amyloid-beta peptide suggest a conserved toxic function.

Authors:  Katia Carmine-Simmen; Thomas Proctor; Jakob Tschäpe; Burkhard Poeck; Tilman Triphan; Roland Strauss; Doris Kretzschmar
Journal:  Neurobiol Dis       Date:  2008-11-08       Impact factor: 5.996

6.  Intraneuronal APP, not free Aβ peptides in 3xTg-AD mice: implications for tau versus Aβ-mediated Alzheimer neurodegeneration.

Authors:  Matthew J Winton; Edward B Lee; Eveline Sun; Margaret M Wong; Susan Leight; Bin Zhang; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2011-05-25       Impact factor: 6.167

7.  Effect of mouse strain as a background for Alzheimer's disease models on the clearance of amyloid-β.

Authors:  Hisham Qosa; Amal Kaddoumi
Journal:  J Syst Integr Neurosci       Date:  2016-04-30

8.  Differential effects of amyloid-β peptide aggregation status on in vivo retinal neurotoxicity.

Authors:  H R Watts; Pjb Anderson; D Ma; K L Philpott; S M Jen; M Croucher; L S Jen; S M Gentleman
Journal:  Eye Brain       Date:  2010-09-09

Review 9.  Using human induced pluripotent stem cells (hiPSCs) to investigate the mechanisms by which Apolipoprotein E (APOE) contributes to Alzheimer's disease (AD) risk.

Authors:  Sreedevi Raman; Nicholas Brookhouser; David A Brafman
Journal:  Neurobiol Dis       Date:  2020-02-05       Impact factor: 5.996

Review 10.  Transgenic models of Alzheimer's disease: better utilization of existing models through viral transgenesis.

Authors:  Thomas L Platt; Valerie L Reeves; M Paul Murphy
Journal:  Biochim Biophys Acta       Date:  2013-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.